MX384202B - Vesiculas extracelulares derivadas de lisado de plaquetas de humano para ser utilizadas en medicina. - Google Patents

Vesiculas extracelulares derivadas de lisado de plaquetas de humano para ser utilizadas en medicina.

Info

Publication number
MX384202B
MX384202B MX2018015123A MX2018015123A MX384202B MX 384202 B MX384202 B MX 384202B MX 2018015123 A MX2018015123 A MX 2018015123A MX 2018015123 A MX2018015123 A MX 2018015123A MX 384202 B MX384202 B MX 384202B
Authority
MX
Mexico
Prior art keywords
diseases
platelet lysate
human
extracellular vesicles
medicine
Prior art date
Application number
MX2018015123A
Other languages
English (en)
Other versions
MX2018015123A (es
Inventor
Miroschedji Kyra Natalia Matahari De
Original Assignee
Lysatpharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56112904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384202(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lysatpharma Gmbh filed Critical Lysatpharma Gmbh
Publication of MX2018015123A publication Critical patent/MX2018015123A/es
Publication of MX384202B publication Critical patent/MX384202B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/70—General characteristics of the apparatus with testing or calibration facilities

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a lisado de plaquetas de humano o una fracción que está enriquecida respecto a vesículas extracelulares derivadas de lisado de plaquetas de humano y su uso en medicina, particularmente para la prevención y/o tratamiento de enfermedades provocadas por inflamación, enfermedades neurodegenerativas, enfermedades inmunes/autoinmunes, enfermedades cardiovasculares, enfermedades dermatológicas, enfermedades ortopédicas, medicina regenerativa de tejidos, enfermedades oncológicas, enfermedades infecciosas, rechazos de transplante, apoplejía, isquemia o enfermedad de injerto contra hospedero. La presente invención también se refiere a un método para fabricar una preparación farmacéutica o una preparación de diagnóstico o una preparación cosmética que comprende el paso de agregar el lisado de plaquetas de humano o una fracción que está enriquecida respecto a vesículas extracelulares derivadas de lisado de plaquetas de humano a la preparación farmacéutica o una preparación de diagnóstico o una preparación cosmética
MX2018015123A 2016-06-08 2017-06-07 Vesiculas extracelulares derivadas de lisado de plaquetas de humano para ser utilizadas en medicina. MX384202B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16173465.2A EP3254684B1 (en) 2016-06-08 2016-06-08 Human platelet lysate or fraction enriched in human platelet-derived extracellular vesicles, for use in medicine
PCT/EP2017/063868 WO2017211906A1 (en) 2016-06-08 2017-06-07 Human platelet lysate derived extracellular vesicles for use in medicine

Publications (2)

Publication Number Publication Date
MX2018015123A MX2018015123A (es) 2019-10-15
MX384202B true MX384202B (es) 2025-03-14

Family

ID=56112904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015123A MX384202B (es) 2016-06-08 2017-06-07 Vesiculas extracelulares derivadas de lisado de plaquetas de humano para ser utilizadas en medicina.

Country Status (19)

Country Link
US (3) US20190290696A1 (es)
EP (2) EP3254684B1 (es)
JP (2) JP7122976B2 (es)
KR (3) KR20190017896A (es)
CN (2) CN115710574A (es)
AU (1) AU2017276712B2 (es)
BR (1) BR112018075295A2 (es)
CA (1) CA3026004A1 (es)
DK (1) DK3468568T3 (es)
ES (1) ES2832727T3 (es)
HU (1) HUE051792T2 (es)
IL (1) IL263296B (es)
MX (1) MX384202B (es)
PL (1) PL3468568T3 (es)
PT (1) PT3468568T (es)
RU (1) RU2735139C2 (es)
SG (1) SG11201810117WA (es)
WO (1) WO2017211906A1 (es)
ZA (1) ZA201807760B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
EP3254684B1 (en) * 2016-06-08 2019-10-23 Lysatpharma GmbH Human platelet lysate or fraction enriched in human platelet-derived extracellular vesicles, for use in medicine
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
EP3813853A4 (en) 2018-06-29 2022-04-06 Platelet Biogenesis, Inc. DELIVERY COMPOSITIONS AND METHODS OF USE
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12508325B2 (en) 2018-12-20 2025-12-30 Ohio State Innovation Foundation Compositions and methods for reprogramming diseased musculoskeletal cells
US12391922B2 (en) 2019-02-15 2025-08-19 Terumo Kabushiki Kaisha Platelet lysate production method, production system, and bag set
TWI722400B (zh) * 2019-03-18 2021-03-21 佛教慈濟醫療財團法人 間質幹細胞之胞外泌體及其用途
CN110090310B (zh) * 2019-04-01 2021-08-10 东南大学 一种血小板膜自组装纳米气泡及其制备方法和应用
JP7846988B2 (ja) * 2019-04-15 2026-04-16 パール ダイアグノスティクス，インコーポレイティド 疾患および障害の検出のために細胞外小胞を使用する方法および組成物
WO2021016368A1 (en) * 2019-07-22 2021-01-28 Erivan Bio, Llc Topical exosome compositions and associated methods
CN110585243A (zh) * 2019-08-12 2019-12-20 丰泽康生物医药（深圳）有限公司 用于治疗糖皮质激素依赖性皮炎的多潜能细胞活性物与富血小板血浆复合物及制法和应用
CN110339180B (zh) * 2019-08-12 2020-10-09 苏州大学 一种抗炎靶向递送系统及其制备方法
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
EP4013392B1 (en) * 2019-09-13 2026-04-29 Exocure Sweden AB Use of ghost nanovesicles as therapeutics
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
US11951134B2 (en) 2019-09-30 2024-04-09 North Carolina State University Cationic platelet lysate compositions and related methods
AU2021241661A1 (en) * 2020-03-27 2022-11-03 Platelet Biogenesis, Inc. Novel anucleated cells and uses thereof
WO2021195544A1 (en) * 2020-03-27 2021-09-30 Platelet Biogenesis, Inc. Novel anucleated cells for the treatment of diseases
US12377121B2 (en) 2020-04-10 2025-08-05 Zeo Scientifix, Inc. Compositions comprising nanoparticles, method of making and uses thereof
EP4149497A4 (en) * 2020-05-14 2024-06-05 Platelet Biogenesis, Inc. Novel anucleated cells as a source for treatment of platelet rich plasma dependent disorders
KR102384368B1 (ko) 2020-06-18 2022-04-07 경북대학교 산학협력단 섬유아세포 유래 세포외 소포체를 유효성분으로 함유하는 피부 및 점막 창상 치료용 조성물
KR102209937B1 (ko) * 2020-06-22 2021-02-01 주식회사 엑소코바이오 생산성 향상 및 생리활성 강화를 위한 엑소좀의 생산방법 및 이의 응용
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
CN113332312B (zh) * 2021-02-01 2023-02-24 浙江大学医学院附属邵逸夫医院 一种基于物理整粒的自成形血小板纳米囊泡及其制备方法
CN115029309A (zh) * 2021-03-05 2022-09-09 杭州市萧山区中医院 富血小板血浆来源性外泌体的分离方法及其应用
JP7025070B1 (ja) 2021-05-14 2022-02-24 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
DE102021124752A1 (de) * 2021-09-24 2023-03-30 Ad Lentus GmbH Autologes Therapeutikum und Verfahren zur Herstellung desselben
JPWO2023079655A1 (es) * 2021-11-04 2023-05-11
US12213994B2 (en) * 2021-12-08 2025-02-04 Zeo Scientifix, Inc. Compositions and methods for treating pain with extracellular vesicles
JP2025504169A (ja) * 2022-02-01 2025-02-06 ミトリックス・バイオ・インコーポレイテッド 眼障害の処置で使用するための血小板由来ミトコンドリア含有細胞外小胞
CA3252156A1 (en) * 2022-02-24 2023-08-31 Rion Llc COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE SYSTEM
KR102674407B1 (ko) * 2022-02-25 2024-06-12 ㈜클리니크후즈후 혈소판 및 혈액유래 줄기세포를 포함한 혈액유래 엑소좀 제조방법과 이를 통해 제조된 엑소좀
CN114306384B (zh) * 2022-03-08 2022-05-31 北京大学口腔医学院 一种人血小板凋亡微囊泡的应用
AU2023268398A1 (en) * 2022-05-09 2024-11-28 Mitrix Bio, Inc. Platelet-derived extracellular vessicles for treatment of cardiogenic shock and sepsis
TWI857610B (zh) * 2022-05-16 2024-10-01 台灣粒線體應用技術股份有限公司 用於減緩口腔損傷的組合物、其用途及其製備方法
WO2024077117A1 (en) * 2022-10-06 2024-04-11 Capricor, Inc. Method for making vesicles
CN115463154A (zh) * 2022-10-21 2022-12-13 上海君益禾生物医学科技有限公司 一种血小板裂解液和外泌体复合凝胶的制备方法及应用
CN116637201B (zh) * 2023-06-09 2025-10-31 天晴干细胞股份有限公司 一种用于修复牙龈退缩的sPL纳米材料及其制备方法
TW202515588A (zh) * 2023-10-12 2025-04-16 日商耶迪波席茲股份有限公司 製造高濃度血小板血漿之方法
EP4570257A1 (en) * 2023-12-11 2025-06-18 Spirit Scientific Co., Ltd. Use of a purified platelet-derived exosome dry powder for relieving inflammation or injury
EP4578454A1 (en) 2023-12-28 2025-07-02 Lysatpharma GmbH Compositions comprising platelet derived extracellular vesicles
WO2025184489A1 (en) 2024-02-29 2025-09-04 Consano Bio, Inc. Allogeneic human plasma and platelet derived products and uses thereof
EP4620478A1 (en) * 2024-03-22 2025-09-24 Spirit Scientific Co. LTD. Pharmaceutical composition comprising platelet-derived extracellular vesicles of different sizes activated by freeze-thaw cycles, preparation process thereof, and use in promoting wound healing of respiratory tract-related tissues and alleviating inflamma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313151C (zh) * 2002-11-04 2007-05-02 杭州浙大康泰生物技术有限公司 一种新型高效非细胞性疫苗的制备及其用途
US20060116321A1 (en) 2004-07-01 2006-06-01 Robbins Paul D Immunosuppressive exosomes
IT1392897B1 (it) 2008-07-18 2012-04-02 Fond Ircss Ca' Granda - Ospedale Maggiore Policlinico Frazione piastrinica derivante da sangue placentare
DK2373321T3 (en) * 2008-12-05 2016-06-13 Biomed Device S R L Biovedhæftende platelet lysate and compositions thereof for the treatment of mucostitis
ES2402144T3 (es) * 2010-05-25 2013-04-29 Gwowei Technology Co., Ltd. Lisado plaquetario inactivado que contiene factores de crecimiento empobrecido en PDGF y VEGF y su procedimiento de preparación
WO2012020308A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
EP2629782B1 (en) 2010-10-18 2019-02-20 Agency For Science, Technology And Research Use of exosomes derived from mesenchymal stem cells to promote or enhance hair growth
IL210162A0 (en) * 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
CA2840568C (en) 2011-06-27 2021-05-04 Emory University Compositions, uses, and preparation of platelet lysates
TR201908716T4 (tr) 2011-11-23 2019-07-22 Cell Therapy Ltd Platelet lizat jeli.
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
CN104726410B (zh) * 2013-12-23 2019-09-17 浙江大学 一种具有免疫抑制功能的外排体及其应用
WO2016145330A1 (en) 2015-03-11 2016-09-15 Atta Behfar Exosome delivery technology
EP3254684B1 (en) * 2016-06-08 2019-10-23 Lysatpharma GmbH Human platelet lysate or fraction enriched in human platelet-derived extracellular vesicles, for use in medicine

Also Published As

Publication number Publication date
US20250241958A1 (en) 2025-07-31
JP2022116227A (ja) 2022-08-09
CN115710574A (zh) 2023-02-24
EP3254684A1 (en) 2017-12-13
SG11201810117WA (en) 2018-12-28
AU2017276712B2 (en) 2020-03-12
CA3026004A1 (en) 2017-12-14
EP3254684B1 (en) 2019-10-23
IL263296B (en) 2021-08-31
HUE051792T2 (hu) 2021-03-29
US20220000931A1 (en) 2022-01-06
EP3468568B1 (en) 2020-09-02
IL263296A (en) 2018-12-31
CN109310712A (zh) 2019-02-05
MX2018015123A (es) 2019-10-15
EP3468568A1 (en) 2019-04-17
RU2018141006A3 (es) 2020-07-10
KR20220136461A (ko) 2022-10-07
DK3468568T3 (da) 2020-12-07
US20190290696A1 (en) 2019-09-26
JP7122976B2 (ja) 2022-08-22
ES2832727T3 (es) 2021-06-11
WO2017211906A1 (en) 2017-12-14
JP2019517488A (ja) 2019-06-24
PT3468568T (pt) 2020-11-30
BR112018075295A2 (pt) 2019-07-02
RU2735139C2 (ru) 2020-10-28
PL3468568T3 (pl) 2021-05-04
AU2017276712A1 (en) 2018-12-13
NZ748679A (en) 2021-03-26
KR20190017896A (ko) 2019-02-20
RU2018141006A (ru) 2020-07-10
KR20210047983A (ko) 2021-04-30
ZA201807760B (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX384202B (es) Vesiculas extracelulares derivadas de lisado de plaquetas de humano para ser utilizadas en medicina.
MX2025009223A (es) Agentes de union a clec9a y su uso
GEP20217263B (en) Anti-cd27 antibodies
SA518391624B1 (ar) Ror- منظمات جاما
MX2023006541A (es) Formulaciones de dosis fija.
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2017014082A (es) Nuevas proteinas especificas para cd137.
CO2017006523A2 (es) Compuestos de dicarboxamida de benzazepinas.
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения
EA201391119A1 (ru) Системы доставки наночастиц, их получение и применение
EA201891164A1 (ru) Композиции и способы получения белковых микрочастиц
LT2013015A (lt) Farmacinės kompozicijos
EA201690659A1 (ru) Композиции аморфного магнийзамещенного фосфата кальция и их применение
MY176631A (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
EA201391440A1 (ru) Производные пиразолопиримидина
BR112017024714A2 (pt) métodos para preparação do fator de von willebrand modificado
EA202191115A1 (ru) Новые пиридазины
EP3833390C0 (en) IMPROVING THE ADMINISTRATION OF MEDICATIONS AND OTHER COMPOUNDS TO THE BRAIN AND OTHER TISSUES
EA202091062A1 (ru) Карбоксилхитозан
EP3569249A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE